Literature DB >> 24501317

BCL-2 inhibitor yields high response in CLL and SLL.

.   

Abstract

Preliminary results from an ongoing phase I clinical trial of the B-cell lymphoma-2 oral inhibitor ABT-199 demonstrated an overall response rate of 84% among 67 patients with relapsed or treatment-resistant chronic lymphocytic lymphoma or small lymphocytic lymphoma.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24501317     DOI： 10.1158/2159-8290.CD-NB2013-178

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  Bortezomib for the treatment of non-Hodgkin's lymphoma.

Authors:  Prithviraj Bose; Michael S Batalo; Beata Holkova; Steven Grant
Journal:  Expert Opin Pharmacother       Date:  2014-09-29       Impact factor: 3.889

Review 2.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

Authors:  Michelle R Arkin; Yinyan Tang; James A Wells
Journal:  Chem Biol       Date:  2014-09-18

Review 3.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

Review 4.  Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

Authors:  Pankit Vachhani; Prithviraj Bose; Mohamed Rahmani; Steven Grant
Journal:  Physiol Genomics       Date:  2014-05-13       Impact factor: 3.107

5.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Authors:  Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti
Journal:  Nat Med       Date:  2015-01-19       Impact factor: 87.241

Review 6.  Noxa and cancer therapy: Tuning up the mitochondrial death machinery in response to chemotherapy.

Authors:  Marie-Christine Albert; Kerstin Brinkmann; Hamid Kashkar
Journal:  Mol Cell Oncol       Date:  2014-07-28

7.  BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.

Authors:  C Touzeau; J Ryan; J Guerriero; P Moreau; T N Chonghaile; S Le Gouill; P Richardson; K Anderson; M Amiot; A Letai
Journal:  Leukemia       Date:  2015-07-15       Impact factor: 11.528

Review 8.  The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.

Authors:  Graham Packham; Serge Krysov; Alex Allen; Natalia Savelyeva; Andrew J Steele; Francesco Forconi; Freda K Stevenson
Journal:  Haematologica       Date:  2014-07       Impact factor: 9.941

Review 9.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

10.  New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.

Authors:  Andreea Lucia Stancu; Mitchell R Smith; Alexandru Almasan
Journal:  Discoveries (Craiova)       Date:  2014 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.